ADC Therapeutics SA (ADCT)
NYSE: ADCT
· Real-Time Price · USD
1.31
-0.03 (-2.24%)
At close: May 13, 2025, 3:59 PM
1.26
-4.18%
After-hours: May 13, 2025, 07:30 PM EDT
-2.24% (1D)
| Bid | 1.26 |
| Market Cap | 130.42M |
| Revenue (ttm) | 70.84M |
| Net Income (ttm) | -157.85M |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -0.81 |
| Forward PE | -0.94 |
| Analyst | Buy |
| Ask | 1.31 |
| Volume | 205,851 |
| Avg. Volume (20D) | 336,269 |
| Open | 1.37 |
| Previous Close | 1.34 |
| Day's Range | 1.25 - 1.37 |
| 52-Week Range | 1.05 - 4.43 |
| Beta | 1.55 |
About ADCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ADCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ADCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
ADC Therapeutics SA is scheduled to release its earnings on May 14, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+9.77%
ADC Therapeutics shares are trading higher after t...
Unlock content with
Pro Subscription
5 months ago
+63.02%
ADC Therapeutics shares are trading higher after the company announced it will provide an initial data update its LOTIS-7 clinical trial.
1 month ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
